Ciprofloxacin for the treatment of Cardiobacterium hominis prosthetic valve endocarditis

Lisa M. Avery  
*St. John Fisher University*, lavery@sjf.edu

Catherine B. Felberbaum  
*Unity Hospital*

Muhammad Hasan  
*St. Joseph's Health*

Follow this and additional works at: [https://fisherpub.sjf.edu/pharmacy_facpub](https://fisherpub.sjf.edu/pharmacy_facpub)

Part of the Pharmacy and Pharmaceutical Sciences Commons

Publication Information


Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit [http://libguides.sjfc.edu/citations](http://libguides.sjfc.edu/citations).

This document is posted at [https://fisherpub.sjf.edu/pharmacy_facpub/161](https://fisherpub.sjf.edu/pharmacy_facpub/161) and is brought to you for free and open access by Fisher Digital Publications at . For more information, please contact fisherpub@sjf.edu.
Ciprofloxacin for the treatment of Cardiobacterium hominis prosthetic valve endocarditis

Abstract
Prosthetic valve endocarditis due to Cardiobacterium hominis is rare and recommended therapy includes a third generation cephalosporin. We report a case of Cardiobacterium hominis endocarditis post transcatheter aortic valve replacement in a patient with significant beta-lactam antimicrobial sensitivities who was successfully treated with ciprofloxacin monotherapy in conjunction with surgery.

Disciplines
Pharmacy and Pharmaceutical Sciences

Comments
This open access article is also available through the publisher: https://doi.org/10.1016/j.idcr.2018.01.016

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Case report

Ciprofloxacin for the treatment of *Cardiobacterium hominis* prosthetic valve endocarditis

Lisa M. Avery, Catherine B. Felberbaum, Muhammad Hasan

**ARTICLE INFO**

Keywords: Cardiobacterium Endocarditis Ciprofloxacin Fluoroquinolones

**ABSTRACT**

Prosthetic valve endocarditis due to *Cardiobacterium hominis* is rare and recommended therapy includes a third generation cephalosporin. We report a case of *Cardiobacterium hominis* endocarditis post transcatheter aortic valve replacement in a patient with significant beta-lactam antimicrobial sensitivities who was successfully treated with ciprofloxacin monotherapy in conjunction with surgery.

**Case report**

A 78-year-old man was referred to the hospital by his primary care physician for intravenous antibacterial therapy after 2 sets of blood cultures grew *Cardiobacterium hominis*. One week earlier he had been hospitalized for exertional chest tightness radiating into his jaw, bilateral peripheral edema, and severe anemia due to lower gastrointestinal blood loss. Troponin was mildly elevated at 0.2 ng/mL, BNP was 671 pg/mL and electrocardiogram showed sinus rhythm with nonspecific repolarization changes. His hemoglobin was 6.7 g/dL and he received 2 units of packed cells. During the transfusion he developed a fever of 38.9 °C, so 2 sets of peripheral blood cultures were drawn. He had no additional fevers, received no antimicrobials during that hospital stay, and was discharged. Both blood culture sets grew *Cardiobacterium hominis*, so the patient was asked to return to the hospital.

On readmission he reported a history of intermittent low grade fevers, chills, increasing fatigue, worsening anemia, and bilateral leg swelling unresponsive to diuretics over the last 4 months. He had a history of chronic systolic and diastolic congestive heart failure, hypertension, hyperlipidemia, and prostate cancer status post radiation treatments.

Vital signs on admission included a temperature of 36.9 °C, heart rate of 94 beats per minute, respiratory rate of 18 breaths per minute, blood pressure of 132/57 mm Hg. Oxygen saturation was 99% on room air. On physical exam a systolic murmur was noted with no peripheral signs of endocarditis. The white blood cell count was 9.4 × 10³/µL, hemoglobin: 8.6 g/dL, and platelets were 210 × 10³/µL. The sedimentation rate was 75 mm/h, and C-reactive protein of 11.4 mg/dL. The blood urea nitrogen (BUN) was elevated at 37 mg/dL with a serum creatinine of 1.25 mg/dL. A transesophageal echocardiogram (TEE) revealed a small vegetation or mass on the aortic valve with a mild to moderate perivalvular leak and no abscess.

Because the patient reported a history of tongue swelling on cefazolin and a rash on penicillin, ciprofloxacin 400 mg intravenously every 12 h was begun. The isolate was sent to a reference laboratory for sensitivity testing. Minimum inhibitory concentration for the following antimicrobials was reported: ampicillin: 0.25 ug/mL (beta-lactamase negative), ceftriaxone: 1 ug/mL, ciprofloxacin: ≤0.12 ug/mL, levofloxacin: ≤0.06 ug/mL, meropenem: 0.12 ug/mL, trimethoprim-sulfamethoxazole: 0.5/9.5 ug/mL. Repeat blood cultures were negative 4 days after the initiation of ciprofloxacin therapy.

On day 6 of hospitalization, the patient experienced chest pressure radiating into his jaw. This occurred 3 days after clopidogrel and aspirin had been held for esophagogastroduodenoscopy and colonoscopy to work up gastrointestinal bleeding. Troponin was 0.08 ng/mL and...
spectrometry (MALDI-TOF) technology that augments a laboratory advent of matrix assisted laser desorption ionization-time of flight mass spectrometry [2]. There are only six published case reports of endocarditis that utilize ciprofloxacin [2]. Patients with endocarditis who are unable to tolerate third or fourth-generation cephalosporin for treatment of HACEK endocarditis [2]. The American Heart Association/Infectious Disease Society of America endocarditis guidelines recommend ceftriaxone or another member of the HACEK (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens and Kingella species) group of bacteria known for their slow growing nature and insidious onset [1]. HACEK organisms are the causative pathogens in < 10% of cases of community acquired infectious endocarditis, excluding infections in intravenous drug users [2]. This percentage may increase with the advent of matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) technology that augments a laboratory’s ability to detect this pathogen [3].

The Electrocardiogram showed a myocardial infarction with anterolateral ST elevation. Emergent cardiac catheterization revealed severe left main and right coronary artery stenosis of 99%. The patient underwent emergent cardiac surgery consisting of removal of the SAPIEN valve, coronary artery bypass graft × 3, and aortic valve replacement. The surgeon stated that the SAPIEN valve was very difficult to remove due to many small vegetations on all of the leaflets, as well as below the leaflets and between the native valve and the SAPIEN valve (Fig. 1).

On post-operative day 7 the patient developed a mediastinal and left chest hematoma that led to cardiogenic shock and he was transferred to the intensive care unit. He returned to the operating room for post-operative bleeding where 2 liters of blood were removed from the right chest. He remained in the intensive care unit for 8 days. On post-operative day 15, the antibacterial was converted to oral ciprofloxacin 500 mg twice daily. This was administered for an additional 4 weeks, resulting in a total of a 6.5 weeks (6 weeks post-surgery) of treatment. He received no other antimicrobials during hospitalization with the exception of vancomycin for surgical prophylaxis. After a 2.5 week hospital stay he was discharged to a rehabilitation center. Fourteen months later, the patient is home, clinically stable with no signs of recurrence. He did not experience any adverse events associated with ciprofloxacin therapy. Levofloxacin was recommended for dental prophylaxis.

Discussion

Cardiobacterium hominis is a gram negative coccobacillus and a member of the HACEK (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens and Kingella species) group of bacteria known for their slow growing nature and insidious onset [1]. HACEK organisms are the causative pathogens in < 10% of cases of community acquired infectious endocarditis, excluding infections in intravenous drug users [2]. This percentage may increase with the advent of matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) technology that augments a laboratory’s ability to detect this pathogen [3].

The American Heart Association/Infectious Disease Society of America endocarditis guidelines recommend ceftriaxone or another third or fourth-generation cephalosporin for treatment of HACEK endocarditis [2]. Patients with endocarditis who are unable to tolerate first line therapy can be treated with a fluoroquinolone (ciprofloxacin, levofloxacin, or moxifloxacin) for 6 weeks based on limited evidence [2]. There are only six published case reports of Cardiobacterium hominis that utilize ciprofloxacin as part of combination therapy or as salvage therapy [4–9] (Table 1). Clinical cure was achieved in 5 of the 6 patients [4–8] with surgical intervention in 3 patients [7–9]. In 4 cases, ciprofloxacin was combined with either rifampin, ceftriaxone, ceftriaxone and gentamicin, or penicillin, gentamicin, and imipenem- cilastatin [5,6,8,9]. Our case report is unique in that ciprofloxacin monotherapy was used for the entire course of therapy, including step-down to oral ciprofloxacin to complete 6 weeks of treatment avoiding the long term use of a peripherally inserted central line.

Susceptibility testing for Cardiobacterium hominis is not readily available at most institutions. In our case the organism was sent to a reference laboratory and was found to be sensitive to all antimicrobials tested including ciprofloxacin with an MIC of ≤0.12 ug/mL. This is well below the Clinical and Laboratory Standards Institute (CLSI) breakpoint of ≤1 ug/mL [10]. It is also in the range of MIC values 0.012–0.5 ug/mL reported in the literature [4,5,7]. In the case report by Vogt et al., the authors performed a killing curve assay using the patient’s serum after receiving ciprofloxacin 200 mg combined with 5 × 10^5 cfu/mL of organisms. With ciprofloxacin peak and trough concentrations of 0.74 ug/mL and 0.14 ug/mL bacterial counts were undetectable within 2 and 4 h respectively [4].

Cardiobacterium hominis has a strong association with aortic valve infection and is known to produce large friable vegetations [1]. Surgical intervention is required in 30–50% of patients [1,11]. Peripheral and central nervous system emboli are reported in 51 and 21% of cases respectively [11]. Our patient did not have any evidence of peripheral or central nervous system emboli. Acute coronary syndrome is a rare manifestation of endocarditis, but has been reported with other HACEK organisms, including two cases with Cardiobacterium hominis [8,12]. In a case series of patients with endocarditis that presented with acute coronary syndrome, Courand et al. recommended consideration of septic coronary embolism in patients with acute coronary syndrome, elevation of inflammatory biomarkers, a normal coronary artery, and unusual regurgitant valvulopathy [12]. Interestingly in our case the patient presented with acute coronary syndrome that may have been related to septic emboli, although he had an extensive cardiac history.

HACEK endocarditis is associated with a 93% cure rate and 4% rate of hospital mortality [1,11]. Our patient responded well to a 6 week course of ciprofloxacin therapy given first intravenously and then by mouth, in combination with surgical intervention. He also did not experience any adverse reactions that can be associated with long term fluoroquinolone therapy such as QTc prolongation, peripheral neuropathy, or tendon rupture [13].

Conclusion

Monotherapy with intravenous ciprofloxacin followed by oral step down therapy for 6 weeks combined with valve replacement was successful in the treatment of prosthetic aortic valve endocarditis with
### Table 1

<table>
<thead>
<tr>
<th>Age/Gender</th>
<th>Type of Valve</th>
<th>Treatment regimen (reason for ciprofloxacin treatment)</th>
<th>Ciprofloxacin MIC (ug/mL)</th>
<th>Duration of Total Therapy, weeks (Duration of Ciprofloxacin Therapy, weeks)</th>
<th>Result</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>66/F [7]</td>
<td>Native Aortic valve</td>
<td>Ceftriaxone 2 g IV twice daily for 3 weeks, then ciprofloxacin 400 mg IV twice daily (ceftriaxone allergy)</td>
<td>0.012 ≤ 0.12</td>
<td>24 (21)</td>
<td>Cured (NS)</td>
<td></td>
</tr>
<tr>
<td>75/M [9]</td>
<td>Porcine aortic valve/native mitral valve</td>
<td>Ciprofloxacin 400 mg IV twice daily, gentamicin 7 mg/kg/day, ciprofloxacin 400 mg IV twice daily (combination therapy)</td>
<td>0.5 NS</td>
<td>20 days (20 days)</td>
<td>Yes</td>
<td>Died</td>
</tr>
<tr>
<td>66/F [6]</td>
<td>Tissue aortic valve</td>
<td>Ciprofloxacin PO (combination therapy)</td>
<td>≤ 0.12 NS</td>
<td>NS</td>
<td>Yes Post antibiotic treatment</td>
<td></td>
</tr>
<tr>
<td>61/M [5]</td>
<td>Aortic Homograft</td>
<td>Ceftriaxone 2 g IV daily for 3 weeks, then ciprofloxacin 750 mg PO twice daily (renal dysfunction)</td>
<td>0.06 0.06</td>
<td>27 (27)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>43/NS [4]</td>
<td>Aortic Stent Valve</td>
<td>Ciprofloxacin 400 mg IV twice daily to 500 mg PO twice daily (Pencillin and cephalosporin allergy)</td>
<td>≤ 0.12</td>
<td>NS (5) 6.5</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>78/M</td>
<td>Aortic SAPIEN</td>
<td>Ciprofloxacin 400 mg IV twice daily to 500 mg PO twice daily (Penicillin and cephalosporin allergy)</td>
<td>≤ 0.12</td>
<td>24 (21)</td>
<td>Yes Cured (14)</td>
<td></td>
</tr>
<tr>
<td>66/F [8]</td>
<td>Tissue aortic valve</td>
<td>Ceftriaxone 2 g IV twice daily, gentamicin 7 mg/kg/day, ciprofloxacin 400 mg IV twice daily (combination therapy)</td>
<td>0.5 NS</td>
<td>6 (1)</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>63/M [6]</td>
<td>Native Aortic valve</td>
<td>Ceftriaxone 2 g IV twice daily,gentamicin 7 mg/kg/day, ciprofloxacin 400 mg IV twice daily (combination therapy)</td>
<td>0.012 ≤ 0.12</td>
<td>27 (27)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>58/NS</td>
<td>Native Aortic valve</td>
<td>Mezlocillin and tobramycin switched to mezlocillin 4 g IV q8h for unknown duration switched to ciprofloxacin 400 mg IV for 1 dose, then 200 mg IV twice daily (renal dysfunction)</td>
<td>≤ 0.12</td>
<td>22 (22)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>72/M [2]</td>
<td>Aortic homograft</td>
<td>Ceftriaxone and ciprofloxacin PO (combination therapy)</td>
<td>NS</td>
<td>NS</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>63/M [6]</td>
<td>Native Aortic valve</td>
<td>Ceftriaxone 2 g IV twice daily for 3 weeks, then ciprofloxacin 750 mg PO twice daily (ceftriaxone allergy)</td>
<td>NS</td>
<td>NS</td>
<td>Yes Cured b (NS)</td>
<td></td>
</tr>
<tr>
<td>63/M [8]</td>
<td>Native Aortic valve</td>
<td>Ciprofloxacin 400 mg IV twice daily (combination therapy)</td>
<td>≤ 0.12</td>
<td>NS</td>
<td>Yes</td>
<td>Cured (8)</td>
</tr>
<tr>
<td>80/M [10]</td>
<td>Aortic Stent Valve</td>
<td>Ceftriaxone 2 g IV daily for 3 weeks, then ciprofloxacin 750 mg PO twice daily</td>
<td>≤ 0.12</td>
<td>6 (1)</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>66/F [7]</td>
<td>Native Aortic valve</td>
<td>Ceftriaxone 2 g IV twice daily,gentamicin 7 mg/kg/day, ciprofloxacin 400 mg IV twice daily (combination therapy)</td>
<td>0.5 NS</td>
<td>6 (1)</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>75/M [9]</td>
<td>Porcine aortic valve/native mitral valve</td>
<td>Ciprofloxacin 400 mg IV twice daily, gentamicin 7 mg/kg/day, ciprofloxacin 400 mg IV twice daily (combination therapy)</td>
<td>NS</td>
<td>NS</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>80/M [10]</td>
<td>Aortic Stent Valve</td>
<td>Ceftriaxone 2 g IV daily for 3 weeks, then ciprofloxacin 750 mg PO twice daily (ceftriaxone allergy)</td>
<td>NS</td>
<td>NS</td>
<td>Yes Cured b (NS)</td>
<td></td>
</tr>
<tr>
<td>63/M [6]</td>
<td>Native Aortic valve</td>
<td>Ceftriaxone 2 g IV twice daily,gentamicin 7 mg/kg/day, ciprofloxacin 400 mg IV twice daily (combination therapy)</td>
<td>0.5 NS</td>
<td>6 (1)</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>72/M [2]</td>
<td>Aortic homograft</td>
<td>Ceftriaxone and ciprofloxacin PO (combination therapy)</td>
<td>NS</td>
<td>NS</td>
<td>No</td>
<td>NS Cured (NS)</td>
</tr>
<tr>
<td>63/M [6]</td>
<td>Native Aortic valve</td>
<td>Ceftriaxone 2 g IV twice daily for 3 weeks, then ciprofloxacin 750 mg PO twice daily (ceftriaxone allergy)</td>
<td>NS</td>
<td>NS</td>
<td>Yes Cured b (NS)</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- NS: Not stated
- IV: intravenous
- PO: oral.

**References**